Switching from Dupilumab to Upadacitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b 4 LEVEL UP Study. J of Skin 2024, 8 (6), s451. https://doi.org/10.25251/skin.8.supp.451.